13375a6e 55c4 4b1e Bee8 76b3d2454d0a 00
Rabeprazole Sodium Tablet, Delayed Release
Product Images NDC 63187-555
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Rabeprazole Sodium (NDC 63187-555). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Image 01
Label for Rabeprazole Sodium 20 mg delayed-release tablets, quantity of 30 tablets. The label includes instructions to dispense a Medication Guide, describes the tablets as yellow, round, biconvex, imprinted with '107' on one side. Manufactured by Torrent Pharmaceuticals Ltd., India, and packaged by Proficient Rx LP, Thousand Oaks, CA. Storage temperature and child safety warnings are also noted.*
Structure (Rabeprazoletab Figure 01)
Chemical structure of Rabeprazole sodium, showing the molecular arrangement with sodium ion (Na) and functional groups including methoxy and sulfoxide components.*
Figure 2 (Rabeprazoletab Figure 02)
A line graph titled 'Mean Daytime Heartburn Scores RAB-USA-2' showing the mean heartburn scores over days relative to a treatment start point (day 0). The graph compares three groups: Placebo, Rabeprazole 10 mg, and Rabeprazole 20 mg. The vertical axis represents mean heartburn scores ranging from 0 to 4, and the horizontal axis shows study days from -14 to 28. The plot illustrates changes in heartburn scores over time for each group.*
Figure 3 (Rabeprazoletab Figure 03)
A line graph titled 'Mean Nighttime Heartburn Scores RAB-USA-2' showing mean heartburn scores over a 28-day study period. The x-axis represents study days from -14 to 28, and the y-axis shows mean scores from 0 to 4. Three groups are plotted: placebo, Rabeprazole 10 mg, and Rabeprazole 20 mg, with the Rabeprazole treatment groups showing lower mean scores post day 0 compared to placebo.*
Figure 4 (Rabeprazoletab Figure 04)
A line graph titled 'Mean Daytime Heartburn Scores RAB-USA-3' comparing mean heartburn scores over time between placebo and Rabeprazole sodium 20 mg groups. The x-axis represents study days ranging from -14 to 28, with day 0 marked. The y-axis shows mean heartburn scores from 0 (none) to 4 (very severe). The graph shows scores decreasing over time, with the Rabeprazole group generally exhibiting lower scores than placebo after day 0.*
Figure 5 (Rabeprazoletab Figure 05)
A line graph titled 'Mean Nighttime Heartburn Scores Rab-USA-3' comparing heartburn severity scores over time between a placebo group (n=58) and a Rabeprazole sodium 20 mg group (n=59). The x-axis represents study days from -14 to 28, and the y-axis represents mean heartburn scores ranging from 0 (none) to 4 (very severe).*
Logo (Rabeprazoletab Figure 06)
Logo (Rabeprazoletab Figure 07)
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
